About Calliditas Therapeutics
Calliditas Therapeutics is a company based in Stockholm (Sweden) founded in 2004. Calliditas Therapeutics has raised $44.83 million across 3 funding rounds from investors including Investinor and Industrifonden. The company has 40 employees as of December 31, 2022. Calliditas Therapeutics has completed 1 acquisition, including Genkyotex. Calliditas Therapeutics offers products and services including TARPEYO and Kinpeygo. Calliditas Therapeutics operates in a competitive market with competitors including Unicycive, Akebia Therapeutics, Alebund, Aurinia Pharmaceuticals and Renalys, among others.
- Headquarter Stockholm, Sweden
- Employees 40 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Calliditas Na Enterprises Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$44.83 M (USD)
in 3 rounds
-
Latest Funding Round
$21.96 M (USD), Series B
Jul 01, 2019
-
Investors
Investinor
& 1 more
-
Employee Count
40
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Calliditas Therapeutics
Calliditas Therapeutics offers a comprehensive portfolio of products and services, including TARPEYO and Kinpeygo.
Treatment specifically designed for IgA nephropathy to manage rare kidney conditions.
Novel medication for rare diseases, focusing on renal and hepatic indications.
People of Calliditas Therapeutics
Unlock access to complete
Funding Insights of Calliditas Therapeutics
Calliditas Therapeutics has successfully raised a total of $44.83M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $21.96 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Calliditas Therapeutics
Calliditas Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Investinor and Industrifonden.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investments in deep-tech, life sciences, and transformative tech are managed.
|
Locked | Locked | Locked |
Investor details for Calliditas Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Calliditas Therapeutics
Calliditas Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genkyotex.
Investment portfolio details for Calliditas Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapeutics are developed to selectively inhibit NOX enzymes.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Calliditas Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Calliditas Therapeutics
Detailed financials for Calliditas Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Calliditas Therapeutics Comparisons
Peer comparison for Calliditas Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Calliditas Therapeutics
Calliditas Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unicycive, Akebia Therapeutics, Alebund, Aurinia Pharmaceuticals and Renalys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapies for kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| Locked | Locked | Locked |
Therapeutics for various kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
|
| Locked | Locked | Locked |
Therapeutics for renal diseases are developed and launched by Renalys.
|
Detailed competitors of Calliditas Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Calliditas Therapeutics
Complete news archive for Calliditas Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Calliditas Therapeutics
Calliditas Therapeutics was founded in 2004 and raised its 1st funding round 9 years after it was founded.
Calliditas Therapeutics is headquartered in Stockholm, Sweden.
Renee Aguiar-Lucander is the current CEO of Calliditas Therapeutics.
Calliditas Therapeutics is a funded company, having raised a total of $44.83M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Calliditas Therapeutics is 40.
Calliditas Therapeutics is involved in the development of small molecule-based drugs for inflammatory kidney diseases. Its leading candidate Nefecon is used in inflammatory kidney disease (IgA nephropathy) for the patients at risk of progressing to renal failure. It releases Budesonide, a Glucocorticosteroid, in the lower ileum and ascending colon of the gastrointestinal (GI) tract. The targeted release of the active ingredient to this region of the GI tract will bypass the systemic side effects of budesonide. The company has also discovered potential uses of this formulation for autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC).
Calliditas Therapeutics's top competitors include Akebia Therapeutics, Gennova and Alebund.
Calliditas Therapeutics offers TARPEYO and Kinpeygo.
Calliditas Therapeutics has made 1 acquisition, including Genkyotex.
Calliditas Therapeutics has 2 investors. Key investors include Investinor, and Industrifonden.